🔗 Share this article

While the US continues making unprecedented changes to its vaccine guidelines, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 shots during the global health crisis and has concentrated on alleged fatalities after Covid immunization in her short position at the FDA.

Scheduled Overhauls to Pediatric Vaccine Schedule

Agency leaders were set to reveal radical changes to the pediatric immunization program earlier this month, aligning the US with Denmark’s immunization schedule, it is understood – a significant shift that would put the US out of step with many the global community with insufficient data for public health gain. The planned update has been postponed until the next year.

In place of the director of the vaccine center, Høeg is set to address the audience at the gathering. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to lead the office this calendar year.

A Shift at the Regulatory Body

This interim role may indicate a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it suggests a renewed priority upon rolling back already-approved vaccines at the FDA.

Høeg has often pushed for discontinuing specific pediatric vaccine recommendations in the US to become more similar to the Danish model, a nation with nationalized medicine and a population approximately the population of Wisconsin’s.

In her initial comments, she has continued to focus on vaccination policy – typically the domain of Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Questions Over Expertise

Høeg has no apparent track record in pharmaceutical research, oversight or management, which has been customary for past heads of the CBER. She has served at the FDA as a senior adviser to the commissioner and CBER since March.

“She appears not to have any of the qualifications” for leading the CDER, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in running a sizeable institution. She lacks background in industry regulation.”

Previous heads of CBER would “grasp legal statutes and the underlying principles of medication creation”, said a former acting FDA commissioner. “Frankly, she has not acquired the type of experience that prior appointees who headed CBER have had.”

The drug center has an vast range of responsibilities at the agency, Woodcock stated.

“Many people just zeroes in on the novel medication approvals, but the generic program authorizes thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and more, and each of these need to be managed,” Dr. Woodcock said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a significant administrative element to the role, which supervises in excess of 5,000 employees. “It’s a enormous administrative position, if you perform it correctly,” she said.

Agency Reaction and Contentious Policies

In response to inquiries about Dr. Høeg's qualifications and whether this assignment indicates more teamwork among agency officials on immunizations, a representative said that the “concerns rely on inaccurate premises”.

“Her resume is consistent with the responsibilities of her job,” the representative stated, noting the months Høeg spent counseling the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg inherits the agency head's recently launched fast-track approval initiative, a contentious one-day therapy clearance system that apparently worried her former heads. “How are these therapies being chosen for this fast-track system? Who is making the calls?” Howard said. “There’s a lot of confidentiality happening at the FDA right now.”

In general, he stated, “the Food and Drug Administration seems to be moving towards less stringent rules of most medications, with the exception of vaccines.”

Established Track Record on Vaccines

Concerning vaccines, Høeg has a more established, if problematic, track record, some experts said. She published a study using unconfirmed crowd-sourced reports to estimate the incidence of heart inflammation following COVID-19 immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccines are pose a greater threat than they are.

Part of her “desired changes” for the new government encompassed changing guidelines for new vaccines and ending “optional” vaccines, she said after the election on a audio program. At the FDA, Høeg has reportedly suggested preventing teenage boys from receiving Covid vaccinations.

“She’s an thorough true believer who commences with her conclusions and tailors the evidence to fit the evidence in a very disingenuous, dishonest manner,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|